•Non-alcoholic Steatohepatitis (NASH)
Also known as: Metabolic Dysfunction-associated Steatohepatitis (MASH) / Metabolic Associated-dysfunction Steatohepatitis (MASH) / Metabolic Dysfunction Associated Steatohepatitis (MASH) / NASH/MASH / MASH / Nash / Non-alcoholic Steatohepatitis (MASH) / NASH - Nonalcoholic Steatohepatitis / Non-Alcoholic Steato-Hepatitis (NASH) / Non-alcoholic Steatohepatitis NASH / NASH (Non-alcoholic Steato-hepatitis) / Non Alcoholic Steatohepatitis (NASH) / Nonalcoholic Steatohepatitis (NASH) / Non-Alcoholic Steatohepatitis(NASH) / NASH (Nonalcoholic Steatohepatitis) / NASH (Non-Alcoholic Steatohepatitis) / Non-Alcoholic Steatohepatitis (NASH) / Non Alcoholic Steato Hepatitis / Non-Alcoholic Steato-Hepatitis / Steatohepatitis, Nonalcoholic / Non-Alcoholic Steatohepatitis / Non Alcoholic Steatohepatitis / Nonalcoholic Steatohepatitis / Nonalcoholic steatohepatitis (disorder)
Drug | Drug Name | Drug Description |
---|---|---|
DB12914 | Resmetirom | A thyroid hormone receptor-beta agonist used to treat noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis in adults. |
DB09298 | Silibinin | A flavonolignan with hepatoprotective effects used to treat toxic liver damage and as an adjunct in the management of chronic conditions such as cirrhosis and hepatitis. |